NCT01839279View on ClinicalTrials.gov

A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial

PHASE2CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

May 31, 2014

Conditions
Spasticity
Interventions
DRUG

Tizanidine

DRUG

Placebo

DRUG

Moxifloxacin

Trial Locations (1)

75247

Covance- Dallas, Dallas

Sponsors
All Listed Sponsors
lead

Acorda Therapeutics

INDUSTRY

NCT01839279 - A Study to Define the ECG Effects of Tizanidine Compared to Placebo and the Positive Control, Moxifloxacin, in Healthy Men and Women Using a Blinded ECG Evaluator: A Thorough ECG Trial | Biotech Hunter | Biotech Hunter